Loading
companiesCompany
Remix Therapeutics
Remix Therapeutics is a Massachusetts biotech that makes small molecules to change how RNA is processed; REM-422 destroys the messenger RNA for the transcription factor MYB, a driver of adenoid cystic carcinoma and acute myeloid leukaemia.
Also called: Remix Therapeutics, Inc.
Overview
Remix Therapeutics uses its REMaster platform to design small molecules that reprogramme RNA splicing and stability. REM-422 induces a poison exon in MYB mRNA, marking it for degradation and lowering MYB protein; it is in phase 1 trials in adenoid cystic carcinoma and in acute myeloid leukaemia and higher-risk myelodysplastic syndromes. The company has partnerships with Janssen and Roche on other RNA-processing targets.
Headquarters
Watertown, Massachusetts, US
Scorecard
All companies#486of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Founded
2019
Phase 2Small-molecule inhibitor
REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.
Similar pages
drugs
Phase 2Small-molecule inhibitor